YD Bio

YD Bio was founded in 2013, with businesses covering three major fields: non-invasive early cancer screening, ophthalmic regenerative medicine, and exosome technology. It focuses on clinical trial services, new drug development, cancer prevention and diagnosis, stem cell and exosome therapies, and is committed to addressing unmet clinical needs for various diseases. The company relies on technological innovation and precision medicine to improve patient outcomes. In addition to its self-developed products, the company is also a well-known supplier of clinical trial drugs and has expanded into the research, development, and distribution of post-marketing auxiliary products.